The generic synod price war is intensifying, and drug companies break their arms to survive?

The trend of price reduction is irreversible Drug economics as an important basis for pricing Hebei Province this time released the "hanging net opinion" the biggest point of view is the classification to determine the hanging network way, a total of 10 categories of eligible drugs can be directly linked to the net is divided into 3 kinds of situation treatment.
the first case is: 1. The state negotiates drugs to negotiate the price directly linked to the net, the network cycle and the negotiation cycle are consistent;
the second scenario is to hang up the net after the price has been negotiated and negotiated.
and the third situation is: for the application to hook up to 3 (including) more than 3 drugs, the need to bid to determine the price of direct network, in accordance with the Hebei Province bid hanging network rules, the maximum elimination rate of up to 50%.
of the three cases mentioned above, the second case "needs to be negotiated and negotiated to determine the price before directly linked to the net" includes six types of drugs: 1. Varieties in the list of drugs in short supply (National Drug Administration (No. 5) (National Health Medicine (2020) determined in the list of drugs in short supply in Hebei Province; And approvethed for registration of innovative drugs in accordance with the Measures for the Administration of Drug Registration (State Administration of Market Supervision and Administration Order No. 27); 3. The state negotiates drugs with the same generic name and the same size of drugs, the declared price is the reference price of the state-negotiated drug price, not higher than the lowest price of other provinces and cities of the country (tender); 4. The state and Hebei Province organizations centralized procurement of drugs in the same generic name type of drugs, the declared price of the national or provincial organizations centralized procurement of drugs in the same price for reference; Through the generic drug consistency evaluation of drugs, to the national hanging network (tender) minimum price declaration, the price of over-rated drug declaration shall not be higher than the same name original research drug and not higher than the drug that has been listed on the net evaluation;
industry insiders said that the above-mentioned six types of drugs, the shortage of drugs negotiations are conducive to "guarantee dispensing price", innovative drug negotiations are to encourage innovation, the country talks with the generic name varieties, the same varieties, the original research drugs and over-evaluation drugs, these three categories are equivalent to the "guidance price", negotiations can control the price of such varieties within the standard range;
, however, there are still some drawbacks to the way drug negotiations are negotiated at this stage.
senior industry expert Liu Mingrui pointed out that the two sides of the negotiations more subjective, Party A more historical data for simple price comparison, Party B in the drug economics also did not do much, can not say the price is moderate so.
so, to some extent, such negotiations are a challenge for businesses.
future, access staff for pharmaceutical companies must be more professional and more negotiating.
, what kind of price strategy should pharmaceutical companies adopt when they participate in negotiations? Liu Mingrui, the shortage of drugs, innovative drugs and existing price standards of varieties, have a very clear reference target, reference price, pharmaceutical companies are just to do the choice of the question.
in addition, with the generic name of the same dosage form no more than 2 varieties, without volume, and the number of hanging network enterprises is relatively loose, enterprises can be based on market size, combined with clinical actual sales to quote.
, however, companies must be aware that the era of high gross margins is over, the trend of price reduction is irreversible, in the grasp of their own cost prices on the basis of negotiations.
, the future of drug economics will be an important basis for pricing, for key products, both want to guarantee the winning bid and want to protect the price, can start with the Pharmacoeconomics report.
the third case mentioned in the "Hanging Net Opinion" mentioned in the "Hanging Net Opinion" is that the production enterprise applies for more than 3 drugs to be listed through bidding to determine the price directly after hanging the net.
in accordance with the requirements of Hebei Province, the number of enterprises bidding to hang the network according to the actual number of declared enterprises to determine, if the number of declared enterprises less than 9 (including 9) the maximum number of registered enterprises for the number of declared enterprises minus 1;
The part of Hebei Province's bid-to-hook-up rules on the number of finalists is similar to the requirements of the national harvest, but there is no limit to the maximum number of finalists, the future may be the same variety of more than a dozen manufacturers can supply the situation.
for enterprises, the more competitors manufacturers, the more full varieties, from the elimination of the rules of the price reduction pressure, especially more than 20 varieties, at least half of the elimination.
there are no level limits, no bonuses, no distinguishable rules, this is also a hint of price reduction for enterprises, some of the original quality level distinction of pharmaceutical companies may face price challenges from other enterprises.
in the bidding net rules, Hebei Province also introduced the second batch of national belt procurement on the "maximum price shall not exceed the minimum price of 1.8 times" provisions: the same generic dosage type of drugs, drugs of different enterprises according to the minimum specification difference ratio, the price from low to high ranking, the highest price should not exceed the minimum price of 1.8 times.
the emergence of two identical declared prices, the above-year in Hebei Province, the pharmaceutical mining platform procurement volume of enterprises for low prices.
on this bidding network rules, Liu Mingrui said, the number of shortlisted enterprises increased, bidding pressure will be reduced in principle, so the introduction of the spread rules to force enterprises to continue to reduce prices;
at the same time, Liu Mingrui also reminded that the national pick in the determination of 1.8 times the rule, there is "units can price a price reduction of 50% or less than 0.1 can also be shortlisted" rules, the lack of these two bottoms, Hebei may appear some enterprises "soldiers out of danger" to give extreme low prices to squeeze away competitors, which will affect the normal clinical drug use.
and, hebei province, this round of hanging network label stake, too low prices may force some enterprises, and eventually lead to the withdrawal of products, rather than price cuts.
the "Hanging Net Opinion" also clearly prohibited the five kinds of situations: 1. two years before the date of application due to quality and other issues by the provincial and above drug supervision and administration departments punishment or quality inspection failed;
, Liu Mingrui said, will be honest evaluation and drug procurement combined, bribery, market disruption and other acts as a condition for the withdrawal of the network, this is a very worthy of attention to the new evaluation model, but also the future country's policy direction.
but Hebei this hanging network project to prohibit the hanging network of 5 kinds of situations, compared with other provincial-level network projects, there is no more innovation in quality evaluation, in the recruitment process through such a provision is not guaranteed the quality of drugs, put an end to the bidding field chaos.
in a sense, the recruitment link is also impossible to solve the quality of drugs together.
in the challenge to seek vitality in the reduction of drug prices and guaranteed supply in the search for a balance in fact, from the beginning of the national volume procurement, has foreshadowed the advent of the era of comprehensive price reduction of generic drugs, the future may form a national negotiations and the country and municipal belt procurement and bidding network of the comprehensive price reduction model, generic drugs "price war" will become more and more intense.
under such a "high pressure", pharmaceutical companies will return to the essence of pharmaceutical enterprises, either to do a solid job in production lean management, the cost of generic drugs to the minimum;
only in this way can companies gain life in the challenges ahead.
however, in the situation of the price of generic drugs is getting lower and lower, there have been new problems, worthy of the attention of all parties concerned, that is, in the bidding and procurement process, if Party A asked for price reduction is too harsh, may also bring The side B "active withdrawal of the network" side effects.
, for example, the "Notice on the Price Adjustment of the Price of the Second Batch of Unselected Drugs" issued by the Shandong Provincial Public Resources Trading Center on May 28shows that 48 drugs are to be withdrawn from the network and 239 drugs are to be suspended.
of the 48 drugs to be removed from the network, 28 have voluntarily applied for the withdrawal of the network.
industry insiders said that enterprises will have a variety of reasons "active withdrawal of the network", but certainly with the price can not be separated from the relationship, the relevant departments in the introduction of enterprises at the same time, there should also be a mechanism so that enterprises can be orderly "exit."
in addition, in the drug companies "actively withdraw the network" of the reality of the situation, how to protect the supply of drugs? Liu Mingrui suggested that you can refer to the "Jiangsu model".
June 3, Jiangsu Province for some products do not want to reduce prices to open a green channel, as long as the products in Accordance with the lowest transaction price in Jiangsu Province, the lowest transaction price of the province, the price may not be as a provincial hanging network price in Jiangsu Province, not to be made public.
this is a balanced approach by the competent authorities in "reducing drug prices" and "guaranteeing supply".
in short, on this issue, the relevant departments should let the market this hand play a greater role.
.